RAC2 and prostate cancer: Nonconserved miR‐608 suppresses prostate cancer progression through RAC2/PAK4/LIMK1 and BCL2L1/caspase‐3 pathways by targeting the 3′‐UTRs of RAC2/BCL2L1 and the coding region of PAK4